Bruker Corporation BRKR today announced that it has been
granted U.S. FDA clearance under Section 510(k) to market its MALDI
Biotyper CA System in the United States for the
identification of Gram negative bacterial colonies cultured from human
specimens.
The MALDI Biotyper CA System includes the bench-top microflex™
MALDI-TOF (matrix-assisted laser desorption ionization time-of-flight)
mass spectrometer, software, IVD labeled reagents, a 48-spot MALDI
target and a library of microorganism reference spectra. Bruker has
conducted a multi-site clinical trial comparing performance of the MALDI
Biotyper CA System to 16S ribosomal RNA gene sequencing. The overall
accuracy of the MALDI Biotyper CA System was
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in